EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement
Rhea-AI Summary
EUDA Health Holdings (NASDAQ: EUDA) announced it entered a securities purchase agreement dated November 26, 2025 to sell a convertible warrant to Streeterville Capital for an aggregate purchase price of US$100,000. The Warrant is exercisable into up to 2,000,000 newly issued ordinary shares at an exercise price of US$6.00 per share and was offered under the company’s Form F-3 shelf registration (File No. 333-282723) with a related prospectus supplement.
The Warrant allows cash-only exercise for 90 days from issuance (subject to extension). The company may require partial forced exercise up to 10% of cumulative dollar trading volume if the share price is ≥ US$7.50 for five consecutive trading days and trading volume in that period is at least US$1,500,000. Management described the financing as flexibility to support expansion across Singapore, Malaysia and China.
Positive
- Immediate cash inflow of US$100,000
- Potential proceeds of up to US$12.0M if 2,000,000 shares are exercised at $6.00
- Financing structured to fund expansion in Singapore, Malaysia and China
Negative
- Potential dilution of 2,000,000 shares if fully exercised
- Warrant includes a forced exercise provision up to 10% of trading dollar volume
- Cash-only exercise window of 90 days may limit non-cash conversion flexibility
News Market Reaction
On the day this news was published, EUDA declined 6.85%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.4% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $9M from the company's valuation, bringing the market cap to $119M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: RFL -1.61%, OMH -0.44%, DUO +8.99%, NYC +1.74%, while CHG is flat. This financing-focused warrant news appears stock-specific rather than part of a sector-wide trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 23 | Geographic expansion | Positive | -15.5% | Subsidiary CK Health Plus expanding into India via partnership with SafeRock India. |
| Oct 20 | Regulatory license | Positive | +1.8% | Malaysia Direct Selling License enabling supplements and wellness centers roll-out. |
| Sep 10 | Acquisition LOI | Positive | -5.4% | LOI to acquire GO POSB and build iPSC lab and facility in China. |
| Sep 04 | Therapy distribution | Positive | -9.1% | Securing T-cell immunotherapy distribution rights in Malaysia at USD 8,000 per treatment. |
| Aug 28 | Acquisition LOI | Positive | -3.3% | LOI to acquire Chemokine Pte Ltd and deepen molecular supplement offering. |
Recent expansion and acquisition announcements were generally followed by negative price reactions, suggesting a pattern of sell-offs on growth-focused news.
This announcement adds a structured warrant financing on November 26, 2025 to an active strategic backdrop. In August–September 2025, EUDA pursued acquisitions of Chemokine and GO POSB and expanded into T-cell immunotherapy at USD 8,000 per treatment, yet those items saw mostly negative price reactions. October brought Malaysia direct selling approval and an India partnership via CK Health Plus. Regulatory filings in November detailed completion of a $1,000,000 convertible note program and a prior $15.0 million CK Health share-based acquisition and related impairment.
Market Pulse Summary
The stock moved -6.8% in the session following this news. A negative reaction despite the company describing this warrant financing as strategic would fit prior patterns, where growth initiatives often preceded price declines. The agreement permits up to 2,000,000 new shares at US$6.00, with forced exercise rights if price and volume thresholds are met. Combined with earlier convertible note activity and acquisition-related share issuance, investors may reassess equity overhang and capital structure complexity when interpreting this announcement.
Key Terms
securities purchase agreement financial
convertible warrant financial
AI-generated analysis. Not financial advice.
SINGAPORE, Dec. 05, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or “the Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it entered into a securities purchase agreement on November 26, 2025 with Streeterville Capital, LLC, a Utah limited liability company, for the sale of a convertible warrant (the “Warrant”) for an aggregate purchase price of US
Streeterville Capital is an investment firm with operations in Utah and Tennessee with investments in companies including Cingulate, the Marygold Companies and Damon Inc.
The Warrant may be exercised for cash for ninety (90) days from the date of issuance, subject to extension by mutual agreement between the Company and Streeterville Capital (the “Cash Exercise Period”). During the Cash Exercise Period, the Warrant may only be exercised for cash, and the Company will have the right to require Streeterville Capital to exercise the Warrant, up to
Mr. Alfred Lim, CEO of EUDA, commented, “This agreement represents another deliberate step in strengthening our capital position and advancing EUDA’s growth strategy. The warrant financing gives us the flexibility to deploy capital into high-return initiatives – including new centers, partnerships and technology – as we broaden our footprint across Asia’s fast-growing non-invasive healthcare market. By combining prudent financing with disciplined execution, we aim to accelerate the expansion of our healthcare ecosystem while creating long-term value for our patients, partners and shareholders.”
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than
Forward-Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com
FAQ
What did EUDA (NASDAQ: EUDA) announce on December 5, 2025 regarding financing?
How many shares can the EUDA warrant convert into and at what price?
What is the cash exercise period and are there extensions for the EUDA warrant?
Under what conditions can EUDA require forced exercise of the warrant?
What is the maximum potential cash the company could receive if all warrants are exercised?
How will this warrant financing be used by EUDA?
